Tokio Marine Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Tokio Marine Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.2K	Buy	+1,905	New	+$26.7K	﹤0.01%	569

Other funds holding NTLA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Tokio Marine Asset Management's NTLA Position: Q2 2026 in Review

Tokio Marine Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 1,905 shares worth $32.2K. The stake represents ﹤0.01% of the portfolio and ranks #569 among its holdings.

130 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Tokio Marine Asset Management held 1,905 shares of Intellia Therapeutics worth $32.2K as of Q2 2026.
Intellia Therapeutics was a new Tokio Marine Asset Management position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Tokio Marine Asset Management's portfolio in Q2 2026, its #569 holding.
130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Tokio Marine Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.